James Peyer - Feb 23, 2022 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role: Director, 10%+ Owner
Signature: /s/ Erin Hoffert, Attorney-in-Fact
Stock symbol: SNSE
Transactions as of: Feb 23, 2022
Transactions value $: $63,950
Form type: 4
Date filed: 2/24/2022, 06:12 PM
Previous filing: Feb 22, 2022
Next filing: Feb 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNSE	Common Stock	Purchase	$9.5K	+2.5K	+0.05%	$3.80	5.21M	Feb 23, 2022	See Footnote	F1
transaction	SNSE	Common Stock	Purchase	$54.5K	+15K	+0.29%	$3.63	5.23M	Feb 24, 2022	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

Content

These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.